BRAF and melanoma: In contrast, YHO-1701 combined with trametinib (MEK inhibitor), vemurafenib, or dabrafenib (BRAF inhibitors) was not preferable, wherein only 4 of 11 drug–cell line pairs were additive or synergistic in the four melanoma cell lines.